** Shares of India's Divi's Laboratories DIVI.NS down
2.08% at 3,653.20 rupees
** Drugmaker's Q1 consol profit slumped 49.2% to 3.56
billion rupees ($42.9 million), while rev dropped more than 21%
EYES ON GROWTH BUT RISKS REMAIN
** Motilal Oswal (maintains "neutral", raises PT to 3,430
rupees) says co "in good stead to grow better than market",
capacity addition growth lever over next 3-5 yrs
** Jefferies (retains "buy", hikes TP to 4,300 rupees from
3,610 rupees) sees sales, margin recovery improving in coming
qtrs, expects growth FY25 onwards on project ramp ups
** Nuvama (downgrades to "reduce" from "hold", sets TP 3,120
rupees) flags pricing pressure and market share saturation for
co, adds core business remains soft
(Reporting by Hritam Mukherjee in Bengaluru)
((Hritam.Mukherjee@thomsonreuters.com;))